JP2014521653A5 - - Google Patents

Download PDF

Info

Publication number
JP2014521653A5
JP2014521653A5 JP2014523015A JP2014523015A JP2014521653A5 JP 2014521653 A5 JP2014521653 A5 JP 2014521653A5 JP 2014523015 A JP2014523015 A JP 2014523015A JP 2014523015 A JP2014523015 A JP 2014523015A JP 2014521653 A5 JP2014521653 A5 JP 2014521653A5
Authority
JP
Japan
Prior art keywords
nitrogen
sulfur
oxygen
ring
independently selected
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014523015A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014521653A (ja
JP6006794B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/048368 external-priority patent/WO2013019561A1/en
Publication of JP2014521653A publication Critical patent/JP2014521653A/ja
Publication of JP2014521653A5 publication Critical patent/JP2014521653A5/ja
Application granted granted Critical
Publication of JP6006794B2 publication Critical patent/JP6006794B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014523015A 2011-07-29 2012-07-26 核内輸送調節因子およびその使用 Active JP6006794B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161513428P 2011-07-29 2011-07-29
US201161513432P 2011-07-29 2011-07-29
US61/513,432 2011-07-29
US61/513,428 2011-07-29
US201261653588P 2012-05-31 2012-05-31
US61/653,588 2012-05-31
PCT/US2012/048368 WO2013019561A1 (en) 2011-07-29 2012-07-26 Nuclear transport modulators and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016176098A Division JP2016199604A (ja) 2011-07-29 2016-09-09 核内輸送調節因子およびその使用

Publications (3)

Publication Number Publication Date
JP2014521653A JP2014521653A (ja) 2014-08-28
JP2014521653A5 true JP2014521653A5 (https=) 2015-08-20
JP6006794B2 JP6006794B2 (ja) 2016-10-12

Family

ID=46682903

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2014523015A Active JP6006794B2 (ja) 2011-07-29 2012-07-26 核内輸送調節因子およびその使用
JP2016176098A Withdrawn JP2016199604A (ja) 2011-07-29 2016-09-09 核内輸送調節因子およびその使用
JP2018006773A Active JP6752235B2 (ja) 2011-07-29 2018-01-18 核内輸送調節因子およびその使用

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016176098A Withdrawn JP2016199604A (ja) 2011-07-29 2016-09-09 核内輸送調節因子およびその使用
JP2018006773A Active JP6752235B2 (ja) 2011-07-29 2018-01-18 核内輸送調節因子およびその使用

Country Status (15)

Country Link
US (5) US9428490B2 (https=)
EP (1) EP2736883B1 (https=)
JP (3) JP6006794B2 (https=)
KR (1) KR102022715B1 (https=)
CN (1) CN103842340B (https=)
AU (2) AU2016213805A1 (https=)
BR (1) BR112014001933A2 (https=)
CA (1) CA2842364A1 (https=)
CL (2) CL2014000224A1 (https=)
EA (1) EA201490406A1 (https=)
MX (1) MX350442B (https=)
PE (1) PE20141003A1 (https=)
SG (1) SG10201609097PA (https=)
UA (1) UA117902C2 (https=)
WO (1) WO2013019561A1 (https=)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2542089B1 (en) 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2665362B1 (en) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
JP6006794B2 (ja) * 2011-07-29 2016-10-12 カリオファーム セラピューティクス，インコーポレイテッド 核内輸送調節因子およびその使用
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
WO2013170068A2 (en) * 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
JO3407B1 (ar) 2012-05-31 2019-10-20 Eisai R&D Man Co Ltd مركبات رباعي هيدرو بيرازولو بيريميدين
US9013997B2 (en) 2012-06-01 2015-04-21 Broadcom Corporation System for performing distributed data cut-through
EP2968278B8 (en) * 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
ME03421B (me) * 2013-06-21 2020-01-20 Karyopharm Therapeutics Inc 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba
WO2014205393A1 (en) * 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
AP2016009020A0 (en) 2013-07-18 2016-02-29 Novartis Ag Autotaxin inhibitors comprising a heteroaromatic ring-benzyl-amide-cycle core
US9487536B2 (en) 2013-11-08 2016-11-08 Board Of Trustees Of The University Of Arkansas Melampomagnolide B derivatives
US9469650B2 (en) 2013-11-08 2016-10-18 Board Of Trustees Of The University Of Arkansas Melampomagnolide B derivatives
ES2739637T3 (es) * 2013-11-28 2020-02-03 Inst Nat Sante Rech Med Métodos y composiciones farmacéuticas para el tratamiento de beta-talasemias
CA2942386A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
WO2015138934A1 (en) 2014-03-13 2015-09-17 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for increasing cftr activity
CA2952862A1 (en) 2014-06-19 2015-12-23 Proteostasis Therapeutics, Inc. Compounds, compositions and methods of increasing cftr activity
KR102608259B1 (ko) 2014-08-15 2023-11-29 카리오팜 쎄라퓨틱스, 인코포레이티드 셀리넥소의 다형태
US9981990B2 (en) 2014-12-03 2018-05-29 Bioventures, Llc Melampomagnolide B dimers
CA2971850A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 5-phenyl- or 5-heteroarylthiazol-2-carboxylic amide useful for the treatment of inter alia cystic fibrosis
US10738011B2 (en) 2014-12-23 2020-08-11 Proteostasis Therapeutics, Inc. Derivatives of 5-(hetero)arylpyrazol-3-carboxylic amide or 1-(hetero)aryltriazol-4-carboxylic amide useful for the treatment of inter alia cystic fibrosis
WO2016105468A1 (en) 2014-12-23 2016-06-30 Proteostasis Therapeutics, Inc. Derivatives of 3-heteroarylisoxazol-5-carboxylic amide useful for the treatment of inter alia cystic fibrosis
MA41253A (fr) 2014-12-23 2017-10-31 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
MA42488A (fr) 2015-07-24 2018-05-30 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
CA2999367C (en) 2015-09-23 2023-09-26 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
CA3000483C (en) 2015-10-06 2024-02-13 Proteostasis Therapeutics, Inc. Compounds, compositions, and methods for modulating cftr
CN105384673B (zh) * 2015-11-09 2017-11-14 南京富润凯德生物医药有限公司 3‑氟代‑氮杂环丁烷衍生物的合成方法
EP3397634A1 (en) * 2015-12-31 2018-11-07 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
US10526295B2 (en) 2015-12-31 2020-01-07 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
EP3407885A4 (en) 2016-01-29 2019-06-19 BioVentures, LLC TRIAZOL DERIVATIVES AND MELAMPOMAGNOLIDE B AND METHOD OF USE THEREOF
BR112018070747B1 (pt) 2016-04-07 2024-01-09 Proteostasis Therapeutics, Inc Átomos de silicone contendo análogos de ivacaftor, composições farmacêuticas e usos terapêuticos
AU2017279027A1 (en) * 2016-06-08 2018-12-20 Glaxosmithkline Intellectual Property Development Limited Chemical Compounds
MA45397A (fr) 2016-06-21 2019-04-24 Proteostasis Therapeutics Inc Composés, compositions et procédés pour augmenter l'activité du cftr
EP3512515A1 (en) 2016-09-16 2019-07-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of systemic mastocytosis
US11602530B2 (en) 2016-11-28 2023-03-14 Biogen Ma Inc. CRM1 inhibitors for treating epilepsy
CN106831731B (zh) * 2017-01-17 2019-11-08 广州市闻皓生物科技有限公司 一种Selinexor原料药的合成方法
EP3601235B1 (en) 2017-03-30 2026-03-04 XWPharma Ltd. Bicyclic heteroaryl derivatives, preparation and therapeutic uses thereof
PL3737665T3 (pl) 2018-01-10 2026-04-20 XWPharma Ltd. Proleki ketaminy, ich kompozycje i zastosowania
WO2019232724A1 (en) * 2018-06-06 2019-12-12 Xw Laboratories, Inc. Compounds as nuclear transport modulators and uses thereof
CN110592141B (zh) * 2018-06-13 2023-07-07 中国科学院上海有机化学研究所 用于调控基因编辑效率的化合物及其应用
CN114042070A (zh) 2018-09-30 2022-02-15 凯瑞康宁生物工程（武汉）有限公司 作为神经元组胺受体-3拮抗剂的化合物及其用途
CN111606890A (zh) * 2019-02-26 2020-09-01 微境生物医药科技(上海)有限公司 含丙烯酰基的核转运调节剂及其用途
JP2020141256A (ja) 2019-02-28 2020-09-03 ソニーセミコンダクタソリューションズ株式会社 復調回路、復調方法、送信装置
CN114040909B (zh) 2019-05-01 2025-06-03 卡尔约药物治疗公司 用于制备xpo1抑制剂以及用于制备xp01抑制剂的中间体的方法
TWI899126B (zh) 2019-12-20 2025-10-01 香港商凱瑞康寧有限公司 ４－纈胺醯氧基丁酸的合成方法
AU2021293941B2 (en) 2020-06-18 2024-03-28 XWPharma Ltd. Pharmaceutical granulations of water-soluble active pharmaceutical ingredients
CN115038432B (zh) 2020-06-18 2023-12-26 凯瑞康宁生物工程（武汉）有限公司 水溶性活性药物成分的控制释放制粒
WO2022020621A1 (en) 2020-07-24 2022-01-27 XWPharma Ltd. Pharmaceutical compositions and pharmacokinetics of a gamma-hydroxybutyric acid derivative
EP4225274A1 (en) 2020-10-05 2023-08-16 XWPharma Ltd. Modified release compositions of a gamma-hydroxybutyric acid derivative
WO2022143779A1 (zh) * 2020-12-29 2022-07-07 南京明德新药研发有限公司 含烯基类化合物及其应用
JP2024511991A (ja) 2021-03-19 2024-03-18 エックスダブリューファーマ リミテッド ガンマ－ヒドロキシ酪酸誘導体の組み合わされた放出製剤の薬物動態
EP4559522A3 (en) 2021-08-13 2025-07-16 XWPharma Ltd. Pharmaceutical compositions and oral dosage forms of ketamine derivatives
CN121001993A (zh) * 2023-02-24 2025-11-21 鲁汶天主教大学 核转运调节剂
CN116514773B (zh) * 2023-04-24 2024-12-03 重庆汉佩生物科技有限公司 一种Verdinexor(KPT-335)及其盐酸盐的合成方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR840000529A (ko) * 1981-07-07 1984-02-25 콘스탄틴 루이스 클레멘트 인돌 유도체의 제조방법
US4778796A (en) * 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
JP3111321B2 (ja) * 1990-02-23 2000-11-20 武田薬品工業株式会社 縮合チアゾール化合物
IL97249A (en) * 1990-02-23 1995-01-24 Takeda Chemical Industries Ltd Compounds of 7,6,5,4-tetrahydrothiazole] B-5,4 [pyridine and compounds of 5,6-dihydro-H4-pyrrolo] D-3,2 [thiazole, their manufacture, and pharmaceutical compositions including or
US5541213A (en) * 1993-06-24 1996-07-30 Eisai Co., Ltd. Propenoic acid derivatives diazole propenoic acid compounds which have useful pharmaceutical utility
US5468353A (en) * 1994-05-05 1995-11-21 Minnesota Mining And Manufacturing Company Mist suppressant for solvent extraction metal electrowinning
EP0793653A1 (en) * 1994-11-23 1997-09-10 Neurogen Corporation Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives; new classes of dopamine receptor subtype specific ligands
US20030018025A1 (en) * 1995-06-07 2003-01-23 Neurogen Corporation, Corporation Of The State Of Delaware Certain 4-aminomethyl-2-substituted imidazole derivatives and 2-aminomethyl-4-substituted imidazole derivatives: new classes of dopamine receptor subtype specific ligands
JPH11513382A (ja) * 1995-10-20 1999-11-16 ドクトル カルル トーマエ ゲゼルシャフト ミット ベシュレンクテル ハフツング ５員複素環化合物、これらの化合物を含む医薬品、それらの使用及びそれらの調製方法
DE69736775T2 (de) * 1996-04-04 2007-08-23 Shionogi & Co., Ltd. Cephemverbindungen und medikamente die diese verbindungen enthalten
AU736854B2 (en) 1996-04-25 2001-08-02 Nissan Chemical Industries Ltd. Ethylene derivatives and pesticides containing said derivatives
US5994398A (en) * 1996-12-11 1999-11-30 Elan Pharmaceuticals, Inc. Arylsulfonamides as phospholipase A2 inhibitors
JP4416198B2 (ja) * 1997-12-19 2010-02-17 武田薬品工業株式会社 アニリド誘導体、その製造法および用途
AU2960599A (en) * 1998-03-30 1999-10-18 Akira Karasawa Quinazoline derivatives
CO5271680A1 (es) * 2000-02-21 2003-04-30 Smithkline Beecham Corp Compuestos
EP1335898B1 (en) * 2000-09-29 2005-11-23 TopoTarget UK Limited Carbamic acid compounds comprising an amide linkage as hdac inhibitors
CN101851173A (zh) * 2001-09-14 2010-10-06 梅特希尔基因公司 组蛋白脱乙酰化酶抑制剂
AU2003287965A1 (en) * 2002-10-24 2004-05-13 Carex Sa Modulation of peroxisome proliferator activated receptors activity
DE10250743A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Amid-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4145230B2 (ja) * 2002-11-01 2008-09-03 武田薬品工業株式会社 神経障害の予防・治療剤
AU2003278600A1 (en) * 2002-11-01 2004-05-25 Takeda Pharmaceutical Company Limited Agent for preventing or treating neuropathy
AU2003291403A1 (en) * 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
EP1599447A1 (en) * 2003-02-28 2005-11-30 Galderma Research & Development, S.N.C. Ligands that modulate lxr-type receptors
RU2361872C2 (ru) * 2004-05-26 2009-07-20 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Циннамидное соединение
AU2005272389B2 (en) * 2004-08-11 2011-08-04 Kyorin Pharmaceutical Co., Ltd. Novel cyclic aminobenzoic acid derivative
WO2006088246A1 (ja) * 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Ｇｐｒ３４受容体機能調節剤
PL1954684T3 (pl) 2005-11-15 2014-10-31 Otsuka Pharma Co Ltd Związek oksazolowy i kompozycja farmaceutyczna
AR059955A1 (es) 2006-03-09 2008-05-14 Eisai R&D Man Co Ltd Compuestos policiclicos no peptidicos, medicamentos que los contienen, y usos para prevenir o tratar enfermedades causadas por la produccion de beta amiloide
CN101466670B (zh) * 2006-04-07 2013-04-17 梅特希尔基因公司 组蛋白脱乙酰酶抑制剂
CN101466687B (zh) 2006-04-18 2012-04-11 日本化学医药株式会社 过氧化物酶体增殖剂激活受体δ的激活剂
KR101130380B1 (ko) 2006-06-13 2012-04-23 상하이 인스티튜트 오브 마테리아 메디카 차이니즈 아카데미 오브 싸이언시즈 헤테로시클릭 비뉴클레오시드 화합물, 그의 제조방법, 약학적 조성물 및 항바이러스성 약제로서의 용도
AU2007277519B2 (en) * 2006-07-27 2011-12-22 Amorepacific Corporation Novel compounds, isomer thereof, or pharmaceutically acceptable salts thereof as vanilloid receptor antagonist; and pharmaceutical compositions containing the same
TWI386405B (zh) * 2006-09-05 2013-02-21 咪唑衍生物
EP1939180A1 (en) 2006-12-20 2008-07-02 sanofi-aventis Heteroarylacrylamides and their use as pharmaceuticals for the stimulation of the expression of endothelial NO synthase
EP1942104A1 (en) * 2006-12-20 2008-07-09 sanofi-aventis Heteroarylcyclopropanecarboxamides and their use as pharmaceuticals
EP2542089B1 (en) 2010-03-05 2017-01-18 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2665362B1 (en) 2011-01-17 2016-03-30 Karyopharm Therapeutics, Inc. Olefin containing nuclear transport modulators and uses thereof
US9152882B2 (en) * 2011-06-17 2015-10-06 Microsoft Technology Licensing, Llc. Location-aided recognition
EP4234545A3 (en) 2011-07-29 2023-09-06 Karyopharm Therapeutics Inc. Hydrazide containing nuclear transport modulators and uses thereof
JP6006794B2 (ja) * 2011-07-29 2016-10-12 カリオファーム セラピューティクス，インコーポレイテッド 核内輸送調節因子およびその使用
WO2013170068A2 (en) 2012-05-09 2013-11-14 Karyopharm Therapeutics, Inc. Nuclear transport modulators and uses thereof
EP2968278B8 (en) 2013-03-15 2019-05-22 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
WO2014152263A1 (en) 2013-03-15 2014-09-25 Karyopharm Therapeutics Inc. Exo olefin-containing nuclear transport modulators and uses thereof
WO2014205393A1 (en) 2013-06-21 2014-12-24 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
ME03421B (me) 2013-06-21 2020-01-20 Karyopharm Therapeutics Inc 1,2,4-triazoli kao modulatori nuklearnog transporta i njihova upotreba

Similar Documents

Publication Publication Date Title
JP2014521653A5 (https=)
JP2016503009A5 (https=)
JP2023514872A5 (https=)
JP2017502940A5 (https=)
JP2017532360A5 (https=)
JP2019527718A5 (https=)
JP2015511638A5 (https=)
JP2014526501A5 (https=)
JP2016526576A5 (https=)
JP2019505541A5 (https=)
RU2015127822A (ru) Ингибиторы энхансера гомолога 2 белка zeste
JP2016525104A5 (https=)
JP2010509375A5 (https=)
RU2017121044A (ru) Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы
JP2013512903A5 (https=)
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
JP2013536193A5 (https=)
JP2013537203A5 (https=)
JP2009538897A5 (https=)
JP2011510080A5 (https=)
JP2009536620A5 (https=)
JP2017537948A5 (https=)
JP2016516043A5 (https=)
JP2008535903A5 (https=)
JP2017514809A5 (https=)